Mobileye Global Inc (MBLY) Options

WMT
Walmart price target raised to $120 from $98 at Citi
Citi raised the firm's price target on Walmart to $120 from $98 and keeps a Buy rating on the shares. The firm expects the company's Q4 earnings to beat consensus estimates and guidance. Citi models reported net sales up 3.9%

Thanks Trader..that says that AZL is using Kochs DLE..not IBATS...I dont know if they are commercially tested already..Oh well, like to know where our first plant is now...whats up next? stay tuned as Iris Jancik stated..Lithium prices must go up as you said..but something is brewing here with IBAT.

Novartis agrees to acquire Anthos for up to $3.1B
Novartis (NVS) announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical company with abelacimab, a late-stage medicine in development for the prevent

I would highly recommand to all the so active daily naysayers to sell all their shares and let this board to facts from the company.

It is so boring to "read" this daily bs that is just due to put a bad picture on a fiberworld changing company.

Yesterday's pr just put

the PR for annual results mentioned release on February 13th. is it a must for them/alwyas after market?
or any suprise here?

You are correct yet again, King 👑 !!!!!!!!!!!!!

IB_ will be door dashing chicken wings and grabbing a 12 pack of Guinness Extra Stout .................

I believe the quarterly report will be ok, as long as nasrat has not diluted more shares but I do not expect a

Suction power reactivates for a limited time only special.)3.05 to 5.08 +'65% has to break $5.44 to test $6s again

phillips

https://www.wsj.com/finance/activist-elliott-ratchets-up-pressure-on-phillips-66-with-over-2-5-billion-stake-af2fc33c?mod=hp_lead_pos11

IBM
IBM initiated with an Outperform at Oppenheimer
Oppenheimer analyst Param Singh initiated coverage of IBM with an Outperform rating and $320 price target.

Can you tweak the sticky board so it looks a little less like the bulletin board in detention hall?

EU says Trump tariffs will trigger firm countermeasures

I won't say it either but we can all see it isn't done yet.  And it's nothing until it's done.  

I guess we will see how it plays out

Says the 🤡 that advised everyone to SELL right before 100,000% run. Yes, seems you are still here giving bad advice. Didn't learn a damn thing from that lesson, lmao.

The Lord returned Trump to his rightful place, as Assistant to President Elon Musk. May they and BLLB all be successful 

all the Nancy out of here, you suck anyway
never had my 000

really getting old and you fail miserably😬🙄

FSLR
First Solar upgraded to Outperform from Neutral at Mizuho
Mizuho analyst Maheep Mandloi upgraded First Solar to Outperform from Neutral with a $259 price target.

😎😎😎😎😎😎😎😎😎😎 good morning 😎😎😎😎😎😎😎😎😎😎😎😎😎😎😎😎😎😎😎😎😎ὠ

https://stockcharts.com/h-sc/ui?s=cyn&p=D&yr=0&mn=3&dy=0&id=p11960084343#google_vignette

Michael Daniels to retire from Board of Directors. 8K made point to state that he's not leaving because of any disagreements with the company. According to ChatGPT, he's 75 years old. It's definitely time for him to enjoy the fruits of Blackberry's labor.

https://ih.advfn.com/st

Something is happening behind the scenes

22875,000

Congress not needed. Try again. 

JMP Securities Reiterates Market Outperform Rating on Enanta Pharmaceuticals (ENTA)
February 11, 2025 4:18 AM EST
JMP Securities analyst Roy Buchanan reiterated a Market Outperform rating and $21.00 price target on Enanta Pharmaceuticals (NASDAQ: ENTA).The analyst .... [Needs subscri